Quantcast

Latest polycythemia vera Stories

2014-08-07 04:21:40

SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose...

2014-07-01 04:21:47

-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a...

2014-05-07 23:11:40

MPN Research Foundation will accept the Abbey S. Meyers leadership award from the National Organization of Rare Disorders (NORD) this May in Washington, DC. Chicago, IL (PRWEB) May 07, 2014 The National Organization of Rare Disorders (NORD) announced on April 1st that the MPN Research Foundation was to be presented with their Abbey S. Meyers Award, given annually to a NORD member organization that has demonstrated exceptional leadership in representing its members. Chairman and Founder...

2014-01-30 23:31:18

Following the discovery of the Calreticulin (CALR) mutation, which accounts for the majority of non JAK/MPL mutations in ET and MF patients, Dr. Robert Kralovics sits down with MPN Research Foundation to discuss the discovery. Chicago, IL (PRWEB) January 30, 2014 In December 2013, Dr. Robert Kralovics sat down to discuss the discovery of a genetic mutation that explains the majority of ET and MF for non-JAK and MPL patients. Click here to watch the video. During the late breaking abstract...

2014-01-07 08:30:05

FT. MYERS, Fla., Jan. 7, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology (ASH) last month. Since then, findings...

2013-12-11 12:12:42

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. State-of-the-art genetic sequencing and analytics tools are being employed in medical research to gain an unprecedented understanding of disease mechanisms and treatments. In the search to improve understanding of disease, two studies...

2013-03-18 10:28:27

Researchers at Albert Einstein College of Medicine of Yeshiva University and the Icahn School of Medicine at Mount Sinai have found that macrophages — white blood cells that play a key role in the immune response — also help to both produce and eliminate the body's red blood cells (RBCs). The findings could lead to novel therapies for diseases or conditions in which the red blood cell production is thrown out of balance. The study, conducted in mice, is published today in the...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related